Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Inclusion Criteria

• •Subjects must have a diagnosis of advanced (unresectable or metastatic) sarcoma, for which trabectedin treatment is indicated
• •Subjects must have received prior anthracycline treatment; subjects who failed to tolerate it or for whom it is not clinically appropriate in the opinion of their treating physician may be included
• •All ongoing toxicities related to prior therapy must be resolved to grade 1 or better (except alopecia)
• •Total bilirubin level =\< upper limit of normal (ULN) mg/dL
• •Aspartate aminotransferase (AST) =\< 2.5 x ULN
• •Alanine aminotransferase (ALT) =\< 2.5 x ULN
• •Alkaline phosphatase \< 2.5 x ULN
• •Serum creatinine =\< 1.5 x ULN
• •Calculated creatinine clearance \>= 30 mL/min using the Cockcroft-Gault formula may be included
• •Creatine phosphokinase (CPK) =\< 2.5 x ULN
• •Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L
• •Platelet count \>= 100 x 10\^9/L
• •Hemoglobin \>= 9 g/dL
• •Baseline left ventricular ejection fraction (LVEF) 45% or greater (by echocardiogram or multigated acquisition scan \[MUGA\] study) and no evidence of New York Heart Association class ll to IV heart failure
• •Subjects with lesions safely accessible for biopsy, in the opinion of the treating physician and/or interventional radiology
• •Male or non-pregnant and non-breast feeding female:
• •* Females of child-bearing potential must agree to use highly effective contraception without interruption from initiation of therapy and while on study medication and have a negative serum pregnancy test (beta-human chorionic gonadotropin \[hCG\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study treatment; a highly effective method of contraception is defined as one that results in a low failure rate (that is, \< 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
• •* Male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study
• •Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• •Ability to understand and sign informed consent
• •Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures